TY - CHAP M1 - Book, Section TI - Allogeneic Transplantation A1 - Mehta, Rohtesh S. A1 - Hosing, Chitra A2 - Kantarjian, Hagop M. A2 - Wolff, Robert A. A2 - Rieber, Alyssa G. PY - 2022 T2 - The MD Anderson Manual of Medical Oncology, 4e AB - KEY CONCEPTSThe numbers of allogeneic hematopoietic stem cell transplantation (HCT) are increasing over time, with an increasing use of alternative donors, and with increasing use of reduced-intensity conditioning (RIC).Myeloablative conditioning (MAC) for HCT is associated with a lower risk of relapse compared with RIC, but it is also associated with a higher risk of nonrelapse mortality (NRM).Age, performance status, and HCT-specific comorbidity index are some of the predictors of NRM and are taken into consideration along with the risk of relapse of the underlying disease, when deciding about conditioning intensity.Relapse of the underlying disease is the leading cause of deaths after allogeneic HCT, while graft-versus-host disease (GVHD) and infections are the leading causes of NRM after allogeneic HCT.Risk of relapse may be reduced with the use of maintenance therapy after allogeneic HCT, which is an area of active investigation.Novel GVHD prophylaxis strategies are being explored to reduce the risk of GVHD and its associated morbidity and mortality. SN - PB - McGraw Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1190833966 ER -